Riik: Ameerika Ühendriigid
keel: inglise
Allikas: NLM (National Library of Medicine)
PRAZOSIN HYDROCHLORIDE (UNII: X0Z7454B90) (PRAZOSIN - UNII:XM03YJ541D)
Biocon Pharma Inc.
ORAL
PRESCRIPTION DRUG
Prazosin hydrochloride capsules is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and w
Prazosin Hydrochloride Capsules, USP are available containing prazosin hydrochloride, USP equivalent to 1 mg, 2 mg, or 5 mg of prazosin. bottles of 100 capsules (NDC 70377-066-11) bottles of 100 capsules (NDC 70377-067-11) bottles of 100 capsules (NDC 70377-068-11) Store at 25o C (77o F); excursions permitted to 15 to 30o C (59 to 86o F) [See USP Controlled Room Temperature]. Protect from moisture and light. Dispense in a well-closed, light-resistant container as defined by the USP using a child-resistant closure.
Abbreviated New Drug Application
PRAZOSIN HYDROCHLORIDE - PRAZOSIN HYDROCHLORIDE CAPSULE BIOCON PHARMA INC. ---------- _FOR ORAL USE_ DESCRIPTION Prazosin hydrochloride capsules, USP a quinazoline derivative, is the first of a new chemical class of antihypertensives. It is the hydrochloride salt of 1-(4-amino-6,7- dimethoxy-2-quinazolinyl)-4-(2-furoyl) piperazine and its structural formula is: Molecular formula C H N O •HCl It is white or almost white crystalline powder, very slightly soluble in water, slightly soluble in methanol, in dimethylformamide, in dimethylacetamide and in alcohol; practically insoluble in chloroform and in acetone, and has a molecular weight of 419.87. Each capsule, for oral use, contains prazosin hydrochloride, USP equivalent to 1 mg, 2 mg or 5 mg of prazosin. Inert ingredients in the formulations are: colloidal silicon dioxide, magnesium stearate, sodium starch glycolate, sucrose. The empty hard gelatin capsule shells contain gelatin and titanium dioxide. In addition, the 2 mg and 5 mg empty hard gelatin capsule shells contains D&C Red 28, FD&C Blue 1, FD&C Red 3 and FD&C Red 40. The Imprint ink contains black iron oxide, potassium hydroxide, propylene glycol and shellac. FDA approved dissolution test specifications differ from USP. CLINICAL PHARMACOLOGY The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments 19 21 5 4 demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha-blockers, the antihypertensive action of prazosin is usually not accompanied by a reflex tachycardia. Tolerance has not been observed to develop in long termtherapy. Hemodynamic studies have been ca Lugege kogu dokumenti